FAS and breast carcinoma: In a Phase 1 trial (NCT00455416) in patients with early-stage breast cancer, oral EGCG was found to be safe and well tolerated, with evidence of FAS downregulation in tumor tissue and modulation of lipid metabolism (Tuli et al., 2023).